While we’re grateful for the good news that my most recent PET/CT scan was negative for active tumors, we’re a bit wary of immediately stopping chemotherapy and immunotherapy until Johns Hopkins and NIH weighs in with their recommendations. Twice now, my cancer has recurred within 2-3 months of my remission, we’d rather not this be my third.
Dr. Dogra,
As you’re well aware, Ken’s mantle cell lymphoma has been particularly aggressive. Twice after remission, his cancer came back. First after the Nordic Protocol, it recurred around 2 months after treatment. Second after the bone marrow transplant, it recurred 2-3 months after transplant.
Given Ken’s disease progression & history, we wish to continue with the Rituxan treatment until speaking with Dr. Meade on March 19th. If you could please reschedule the Rituxan treatment every Friday as previously scheduled. We’d also want NIH’s recommendations on how we might decrease the possibility of further recurrence.
Previously, it was discussed that Rituxan Therapy as a maintenance chemo for three years would reduce the likelihood of recurrence. Has that changed? Could Ken remain on Rituxan until this has been discussed with Dr. Meade on the 19th?
Thanks,
Victoria & Ken Foreman